The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Day 30 SUVmax to predict progression in patients with LBCL achieving PR after CAR-T therapy
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, summarizes the results of a study investigating clinical features associated with a higher risk of progression in patients with large B-cell lymphoma (LBCL) who achieve a partial response (PR) with axicabtagene ciloleucel (axi-cel). The study found that a maximum standardized uptake volume (SUVmax) above 10 on day 30 was associated with a high risk of progression. This data supports the use of subsequent consolidation therapy in patients with a high SUVmax on day 30. An ongoing study is investigating the use of loncastuximab tesirine with an anti-CD19 antibody-drug conjugate as a consolidation strategy for patients who achieve a PR at day 30. These studies will also help to better understand the biology of these patients. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
